A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)

Exclusion Criteria

• •* Advanced disease is defined as metastatic disease or locally advanced disease that is not amenable to surgery or radiotherapy with curative intent
• •* TNBC is defined as:
• •\<1% staining by immunohistochemistry (IHC) for estrogen (ER) and progesterone (PR) receptors, 0 or 1+ IHC for human epidermal growth factor receptor 2 (HER2), OR
• •Negative for HER2 amplification by in situ hybridization (ISH) for 2+ IHC disease.
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• •Adequate hematologic, hepatic, and renal function.
• •Any significant medical condition including any suggested by Screening laboratory findings that, in the opinion of the Investigator or Sponsor, may place the subject at undue risk from the study.
• •Has ECG abnormalities that make QT interval corrected (QTc) evaluation difficult (e.g., severe morphologic abnormalities).
• •Prior exposure to a pyrrolobenzodiazepine or indolino-benzodiazepine based drug, or known hypersensitivity or contraindication to SC-005 or excipient contained in the drug formulation.